NDAORALTABLET
Lifecycle
Pre-Launch
Data completeness
0/8 — Limited
Drug data last refreshed 8h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Lamivudine; Zidovudine is a fixed-dose combination of two nucleoside reverse transcriptase inhibitors (NRTIs) administered orally as a tablet. This combination is indicated for the treatment of HIV-1 infection and works by inhibiting reverse transcriptase, thereby reducing viral replication. The product is in pre-launch stage under Aurobindo Pharma's development portfolio.
Pre-Launch
Pre-launch stage suggests active market entry preparation with expansion opportunities for commercial, regulatory, and manufacturing teams at Aurobindo.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on this pre-launch product at Aurobindo offers opportunities in market entry strategy, generic commercialization, and operational scaling. Career growth will depend on successful launch execution and market penetration in the global HIV treatment segment.
Brand ManagerField Sales Representative
Worked on LAMIVUDINE; ZIDOVUDINE at Aurobindo Pharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.